secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001628280-24-051374
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024
--------------------------------------------------------------------------------

- Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.
- No disagreements with prior auditor during fiscal years 2023 and 2022 and subsequent interim period.
- No consultations with Crowe regarding application of accounting principles or audit opinion prior to engagement.
- Change follows competitive request-for-proposal process conducted by Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024051374/0001628280-24-051374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024051374/cdxc-20241213.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-051374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer